Oxaliplatin platinum-based therapeutic regulatory update

Sanofi-Synthelabo submitted the last component of its rolling NDA to the FDA for oxaliplatin as a second-line treatment for advanced colorectal cancer. Oxaliplatin has Fast Track designation. ...